These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 26189763

  • 1. Activation of CB2 receptor is required for the therapeutic effect of ABHD6 inhibition in experimental autoimmune encephalomyelitis.
    Wen J, Ribeiro R, Tanaka M, Zhang Y.
    Neuropharmacology; 2015 Dec; 99():196-209. PubMed ID: 26189763
    [Abstract] [Full Text] [Related]

  • 2. WWL70 attenuates PGE2 production derived from 2-arachidonoylglycerol in microglia by ABHD6-independent mechanism.
    Tanaka M, Moran S, Wen J, Affram K, Chen T, Symes AJ, Zhang Y.
    J Neuroinflammation; 2017 Jan 10; 14(1):7. PubMed ID: 28086912
    [Abstract] [Full Text] [Related]

  • 3. Re-examining the potential of targeting ABHD6 in multiple sclerosis: Efficacy of systemic and peripherally restricted inhibitors in experimental autoimmune encephalomyelitis.
    Manterola A, Bernal-Chico A, Cipriani R, Ruiz A, Pérez-Samartín A, Moreno-Rodríguez M, Hsu KL, Cravatt BF, Brown JM, Rodríguez-Puertas R, Matute C, Mato S.
    Neuropharmacology; 2018 Oct 10; 141():181-191. PubMed ID: 30171986
    [Abstract] [Full Text] [Related]

  • 4. WWL70 protects against chronic constriction injury-induced neuropathic pain in mice by cannabinoid receptor-independent mechanisms.
    Wen J, Jones M, Tanaka M, Selvaraj P, Symes AJ, Cox B, Zhang Y.
    J Neuroinflammation; 2018 Jan 08; 15(1):9. PubMed ID: 29310667
    [Abstract] [Full Text] [Related]

  • 5. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination.
    Manterola A, Bernal-Chico A, Cipriani R, Canedo-Antelo M, Moreno-García Á, Martín-Fontecha M, Pérez-Cerdá F, Sánchez-Gómez MV, Ortega-Gutiérrez S, Brown JM, Hsu KL, Cravatt B, Matute C, Mato S.
    Biochem Pharmacol; 2018 Nov 08; 157():189-201. PubMed ID: 30075103
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis.
    Ribeiro R, Yu F, Wen J, Vana A, Zhang Y.
    Neuroscience; 2013 Dec 19; 254():427-42. PubMed ID: 24036373
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Endogenous leukemia inhibitory factor production limits autoimmune demyelination and oligodendrocyte loss.
    Butzkueven H, Emery B, Cipriani T, Marriott MP, Kilpatrick TJ.
    Glia; 2006 May 19; 53(7):696-703. PubMed ID: 16498619
    [Abstract] [Full Text] [Related]

  • 12. Implication of the anti-inflammatory bioactive lipid prostaglandin D2-glycerol ester in the control of macrophage activation and inflammation by ABHD6.
    Alhouayek M, Masquelier J, Cani PD, Lambert DM, Muccioli GG.
    Proc Natl Acad Sci U S A; 2013 Oct 22; 110(43):17558-63. PubMed ID: 24101490
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Epimedium flavonoids ameliorate experimental autoimmune encephalomyelitis in rats by modulating neuroinflammatory and neurotrophic responses.
    Yin LL, Lin LL, Zhang L, Li L.
    Neuropharmacology; 2012 Oct 22; 63(5):851-62. PubMed ID: 22728315
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS.
    Kong W, Li H, Tuma RF, Ganea D.
    Cell Immunol; 2014 Jan 22; 287(1):1-17. PubMed ID: 24342422
    [Abstract] [Full Text] [Related]

  • 17. An Oriental Medicine, Hyungbangpaedok-San Attenuates Motor Paralysis in an Experimental Model of Multiple Sclerosis by Regulating the T Cell Response.
    Choi JH, Lee MJ, Jang M, Kim EJ, Shim I, Kim HJ, Lee S, Lee SW, Kim YO, Cho IH.
    PLoS One; 2015 Jan 22; 10(10):e0138592. PubMed ID: 26444423
    [Abstract] [Full Text] [Related]

  • 18. Novel disease-modifying anti-rheumatic drug iguratimod suppresses chronic experimental autoimmune encephalomyelitis by down-regulating activation of macrophages/microglia through an NF-κB pathway.
    Li G, Yamasaki R, Fang M, Masaki K, Ochi H, Matsushita T, Kira JI.
    Sci Rep; 2018 Jan 31; 8(1):1933. PubMed ID: 29386552
    [Abstract] [Full Text] [Related]

  • 19. Immunoregulation of experimental autoimmune encephalomyelitis by the selective CB1 receptor antagonist.
    Lou ZY, Zhao CB, Xiao BG.
    J Neurosci Res; 2012 Jan 31; 90(1):84-95. PubMed ID: 21922514
    [Abstract] [Full Text] [Related]

  • 20. Ulinastatin attenuates experimental autoimmune encephalomyelitis by enhancing anti-inflammatory responses.
    Feng M, Shu Y, Yang Y, Zheng X, Li R, Wang Y, Dai Y, Qiu W, Lu Z, Hu X.
    Neurochem Int; 2014 Jan 31; 64():64-72. PubMed ID: 24274996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.